New insight of the efficacy trimetazidine in patients with peripheral arterial disease: a meta-analysis.
Ankle-brachial index
Maximum walking distance
Peripheral arterial disease
Trimetazidine
Journal
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology
ISSN: 2090-911X
Titre abrégé: Egypt Heart J
Pays: Germany
ID NLM: 9106952
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
09
01
2024
accepted:
02
03
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
epublish
Résumé
This review aims to examine the impact of trimetazidine on skeletal muscle function in patients suffering from peripheral artery disease (PAD). We searched for studies, both experimental and observational research, concerning the comparison of trimetazidine administration to placebo/standard of care in patients with PAD in PubMed, ScienceDirect, and Cochrane. Meta-analyses of the included studies were performed using Review Manager v5.4. Clinical parameters [ankle-brachial index (ABI) and maximum walking distance (MWD)] were analyzed. Three observational studies involving 378 participants with PAD satisfied predefined criteria. There was no substantial difference between the examined groups' on ABI (pre- and post-intervention) (MD = - 0.06 [- 0.19 to 0.07], p = 0.38, I Current evidence from our meta-analysis suggests the beneficial role of trimetazidine's anti-ischemic effect in PAD patients by improving MWD, while it has an insignificant influence on ABI.
Sections du résumé
BACKGROUND
BACKGROUND
This review aims to examine the impact of trimetazidine on skeletal muscle function in patients suffering from peripheral artery disease (PAD).
METHODS
METHODS
We searched for studies, both experimental and observational research, concerning the comparison of trimetazidine administration to placebo/standard of care in patients with PAD in PubMed, ScienceDirect, and Cochrane. Meta-analyses of the included studies were performed using Review Manager v5.4. Clinical parameters [ankle-brachial index (ABI) and maximum walking distance (MWD)] were analyzed.
RESULTS
RESULTS
Three observational studies involving 378 participants with PAD satisfied predefined criteria. There was no substantial difference between the examined groups' on ABI (pre- and post-intervention) (MD = - 0.06 [- 0.19 to 0.07], p = 0.38, I
CONCLUSIONS
CONCLUSIONS
Current evidence from our meta-analysis suggests the beneficial role of trimetazidine's anti-ischemic effect in PAD patients by improving MWD, while it has an insignificant influence on ABI.
Identifiants
pubmed: 38448715
doi: 10.1186/s43044-024-00461-x
pii: 10.1186/s43044-024-00461-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
31Informations de copyright
© 2024. The Author(s).
Références
Zemaitis MR, Boll JM, Dreyer MA. Peripheral Arterial Disease 2022. https://www.ncbi.nlm.nih.gov/books/NBK430745/ . Accessed 4 Aug 2023
Aday AW, Matsushita K (2021) Epidemiology of peripheral artery disease and polyvascular disease. Circ Res. https://doi.org/10.1161/CIRCRESAHA.121.318535
doi: 10.1161/CIRCRESAHA.121.318535
pubmed: 34110907
pmcid: 8202714
Jelani Q, Petrov M, Martinez SC, Holmvang L, Al-Shaibi K, Alasnag M (2018) Peripheral arterial disease in women: an overview of risk factor profile, clinical features, and outcomes. Curr Atheroscler Rep. https://doi.org/10.1007/s11883-018-0742-x
doi: 10.1007/s11883-018-0742-x
pubmed: 29858704
pmcid: 5984648
Song P, Fowkes FG, Rudan I, Cai Y, Rahimi KD, Zhu Y et al (2020) Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. https://doi.org/10.1016/S2214-109X(20)30117-0
doi: 10.1016/S2214-109X(20)30117-0
pubmed: 32562651
Olin JW, Sealove BA (2010) Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 85:678–692. https://doi.org/10.4065/mcp.2010.0133
doi: 10.4065/mcp.2010.0133
pubmed: 20592174
pmcid: 2894725
Signorelli SS, Marino E, Scuto S, Di Raimondo D (2020) Pathophysiology of peripheral arterial disease (Pad): a review on oxidative disorders. Int J Mol Sci 21:1–14. https://doi.org/10.3390/ijms21124393
doi: 10.3390/ijms21124393
Kim HO, Kim W (2018) Elucidation of the diagnosis and treatment of peripheral arterial disease. Korean Circ J 48:826–827. https://doi.org/10.4070/kcj.2018.0155
doi: 10.4070/kcj.2018.0155
pubmed: 30088357
pmcid: 6110704
Haigh KJ, Bingley J, Golledge J, Walker PJ (2013) Barriers to screening and diagnosis of peripheral artery disease by general practitioners. Vasc Med 18:325–330. https://doi.org/10.1177/1358863X13505673
doi: 10.1177/1358863X13505673
pubmed: 24105616
Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ (2019) Peripheral artery disease: past, present, and future. Am J Med 132:1133–1141. https://doi.org/10.1016/j.amjmed.2019.04.043
doi: 10.1016/j.amjmed.2019.04.043
pubmed: 31150643
Ihsan I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H (2006) Trimetazidine reduces oxidative stress in cardiac surgery. Circ J 70:1169–1173. https://doi.org/10.1253/circj.70.1169
doi: 10.1253/circj.70.1169
Queme LF, Ross JL, Jankowski MP (2017) Peripheral mechanisms of ischemic Myalgia. Front Cell Neurosci. https://doi.org/10.3389/fncel.2017.00419
doi: 10.3389/fncel.2017.00419
pubmed: 29311839
pmcid: 5743676
Mohand-Said S, Jacquet A, Lucien A, Espinasse-Berrod MA, Frasson Correa De Silva M, Sahel (2002) Protective effect of trimetazidine in a model of ischemia-reperfusion in the rat retina. Ophthal Res 34:300–305. https://doi.org/10.1159/000065603
doi: 10.1159/000065603
Chrusciel P, Rysz J, Banach M (2014) Defining the role of trimetazidine in the treatment of cardiovascular disorders: Some insights on its role in heart failure and peripheral artery disease. Drugs 74:971–980. https://doi.org/10.1007/s40265-014-0233-5
doi: 10.1007/s40265-014-0233-5
pubmed: 24902800
pmcid: 4061463
Ezsi CAD (2015) Trimetazidine in practice: review of the clinical and experimental evidence
Xu D, Li J, Zou L, Xu Y, Hu D, Pagoto SL et al (2010) Sensitivity and specificity of the ankle-brachial index to diagnose peripheral artery disease: a structured review. Vasc Med 15:361–369. https://doi.org/10.1177/1358863X10378376
doi: 10.1177/1358863X10378376
Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T et al (2018) 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Eur Heart J 39:763–816. https://doi.org/10.1093/eurheartj/ehx095
doi: 10.1093/eurheartj/ehx095
pubmed: 28886620
Rac-Albu M, Iliuta L, Suzana A, Guberna M, Sinescu C (2014) The role of ankle-brachial index for predicting peripheral arterial disease. Maed J Clin Med 9(3):295–302
Le Faucheur A, Abraham P, Jaquinandi V, Bouyé P, Saumet JL, Noury-Desvaux B (2008) Measurement of walking distance and speed in patients with peripheral arterial disease: a novel method using a global positioning system. Circulation 117:897–904. https://doi.org/10.1161/CIRCULATIONAHA.107.725994
doi: 10.1161/CIRCULATIONAHA.107.725994
pubmed: 18250268
Taylor OJ, Amato A, Hands W, Kempd GJ, Ramaswami G, Nicolaides A et al (1996) Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31p magnetic resonance spectroscopy: a phase II open study. Vasc Med. https://doi.org/10.1177/1358863X9600100401
doi: 10.1177/1358863X9600100401
pubmed: 9552578
Chu YS, Li DX, Zhang M, Jiang TM (2016) Trimetazidine hydrochloride as a new treatment. Eur Rev Med Pharmacol Sci 20(1):188–193
pubmed: 26813473
Vitale C, Marazzi G, Pelliccia F et al (2011) Trimetazidine improves exercise performance in patients with peripheral arterial disease. Pharmacol Res 63(4):278–283. https://doi.org/10.1016/j.phrs.2011.01.003
doi: 10.1016/j.phrs.2011.01.003
pubmed: 21220024
Hu M, Wang D, He T (2019) Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity. Exp Ther Med 17(6):4427–4434. https://doi.org/10.3892/etm.2019.7472
doi: 10.3892/etm.2019.7472
pubmed: 31086577
pmcid: 6488977